Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blue Cross/Blue Shield Testing Generic Drug Ad Themes For 2003

Executive Summary

The Blue Cross/Blue Shield Association is developing an ad campaign with the message that expanded use of generic drugs will free up resources to spend on future medical innovations

You may also be interested in...



California Health Plans Promoting Generics Versus Brand Statins, COX-2s

Four California health plans are mailing $10 coupons to physicians to cover the copay for a new prescription for one of 12 drugs available under the Generic Advantage program

Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings

A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity

Association Health Plans

The Blue Cross/Blue Shield Association is lobbying against association health plans as its top legislative priority in 2003. In a story on BCBSA's approach to the generic drug debate this year, "The Pink Sheet" incorrectly stated the association's position on the health plan issue (1"The Pink Sheet" May 19, 2003, p. 30)...

Related Content

UsernamePublicRestriction

Register

PS041802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel